Loading [a11y]/accessibility-menu.js
 
BibTex RIS Kaynak Göster

İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması

Yıl 2011, Cilt: 64 Sayı: 1, 1 - 5, 01.01.2011

Klara Dalva Mevhibe Bal Gül Sevim Saydam Selime Ayaz İzak Dalva

https://doi.org/10.1501/Tipfak_0000000777

Öz

Anahtar Kelimeler

-

Kaynakça

  • Wellwood JM, Ellis BG, Price RG, et al . Urinary N-acetyl- beta-D-glucosaminidase activities in patients with renal disease. Br Med J. 1975; 3(5980):408-11.
  • Conchic J , Vindlay J, Levvy AG. Mamma- lian glycosidases: Distribution in the body. Biochem J 1959 ;77:318-325
  • Bourbouze R, Baumann FC, Bonvalet JP, et al. Distribution of N-acetyl-beta-D-glucosa- minidase isoenzymes along the rabbit neph- ron. Kidney Int. 1984; 4:636-42
  • Etherington C, Bosomworth M, Clifton I, et al. Measurement of urinary N-acetyl-b-D- glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J Cyst Fibros. 2007; 1:67-73.
  • Moriguchi J, Inoue Y, Kamiyama S, et al. N-acetyl-beta-D-glucosaminidase (NAG) as the most sensitive marker of tubular dys- function for monitoring residents in non- polluted areas. Toxicol Lett. 2009;190(1):1- 8.
  • Jung K, Schulze BD, Sydow K. Diagnostic significance of different urinary enzymes in patients suffering from chronic renal diseas- es. Clin Chim Acta. 1987 ;1683:287-95.
  • Sherman RL, Drayer DE, Leyland-Jones BR, Reidenberg MM. N-acetyl-beta-glu- cosaminidase and beta 2-microglobulin. Their urinary excretion in patients with re- nal parenchymal disease. Arch Intern Med. 1983;143(6):1183-5.
  • Kang HK, Kim DK, Lee BH, et al Uri- nary N-acetyl-beta-D-glucosaminidase and malondialdehyde as a markers of renal dam- age in burned patients. J Korean Med Sci. 2001;16(5):598-602.
  • Kind PR. N-Acetyl-beta-D-glucosamini- dase in urine of patients with renal disease, and after renal transplants and surgery. Clin Chim Acta. 1982 ;119(1-2):89-97.
  • Sandman R, Margules RM, Kountz SL. Urinary lysosomal glycosidases after renal al- lotransplantation: Correlation of enzyme ex- cretion with allograft rejection and ischemia. Clin Chim Acta.1973;45(4):349-59.
  • Goren MP, Wright RK, Osborne S. Two automated procedures for N-acetyl-beta-D- glucosaminidase determination evaluated for detection of drug-induced tubular neph- rotoxicity. Clin Chem. 1986;32(11):2052-5.
  • Meyer BR, Fischbein A, Rosenman K, et al. Increased urinary enzyme excretion in work- ers exposed to nephrotoxic chemicals. Am J Med. 1984;76(6):989-98.
  • Etherington C, Bosomworth M, Clifton I , et al. Measurment of urinary N-Acetyl-beta- D-glucosaminidase in adult patients with cyctic fibrosis: Before, during and after treat- ment with intravenous antibiotics. Journal of Cyctic Fibrosis 2007; 6: 67-73
  • Mariguchi J, Inoue Y, Kamiyama S, et al. N-Acetyl-beta-D-glucosaminidase(NAG) as the most sensitive marker of tubuler dys- function for monitoring residents in non- polluted areas. Toxicology letters 2009; 190:1-8
  • Johnston ID, Jones NF, Scoble JE, et al. The diagnostic value of urinary enzyme measure- ments in hypertension. Clin Chim Acta. 1983;133(3):317-25.
  • Severini G, Aliberti LM, Di Girolamo M. N-acetyl-beta-glucosaminidase isoenzymes in serum and urine of patients with diabetes mellitus Clin Chem. 1988;34(12):2430- 2432
  • National Institute for Clinical Excellence. Management of type 2 diabetes. Renal dis- ease-prevention and early menagement clini- cal guideline. F. London : Natioanal Institute for Clinical Excellence 2002.
  • Basturk T, Altuntaş Y, Kurklu A, ve ark. Urinary N-Acetyl-beta-D-glucosaminidase as an earlier marker of diabetic nephropa- thy and influence of low-dose perindopril/ indapamide combination. Ren Fail 2006; 28(2):125-8
  • Ellis BG, Tucker SM, Thompson AE, et al. Presence of serum and tissue forms of N- acetyl-beta-glucosaminidase in urine from patients with renal disease. Clin Chim Acta. 1975; 64(2):195-202.
  • Kunin C M, Chesny R W, Craig W A, et al. Enzymuria as a glucosaminidase in the gen- eral population and in patients with renal disease . Pediatrics 1987; 62:751-760
  • Vigano A, Cavanna G, Capodaglio P, et al. Methodological and clinical aspects of uri- nary N-acetyl-glucosaminidase in pediatric subjects. Biochem Med. 1981;25(1):26-33.
  • Horak E, Hopfer SM, Sunderman FW Jr. Spectrophotometric assay for urinary N- acetyl-beta-D-glucosaminidase activity.Clin 29. Bauer JD Clinical Laboratory Methods 9th Chem.198; 27(7):1180-5.
  • Noto A, Ogawa Y, Mori S, et al. Simple, rap- id spectrophotometry of urinary N-acetyl- beta-D-glucosaminidase, with use of a new chromogenic substrate. Clin Chem. 1983; 29(10):1713-6.
  • Yuen CT, Price RG, Chattagoon L, et al. Colorimetric assays for N-acetyl-beta-D- glucosaminidase and beta-D-galactosidase in human urine using newly-developed omega-nitrostyryl substrates. Clin Chim Acta. 1982; 124(2):195-204.
  • Tassi C, Mancuso F, Feligioni L, et al. Ex- pression models of urinary N-Acetyl--D- glucosaminidase in patients with chronic renal insufficiancy. Clin Chim Acta 2004; 346:129-133
  • Welwood JM, Price RG, Ellis BG, et al. A note on the practical aspects of the assay of N-acetyl-beta-D-glucosaminidase. Clin Chim Acta 1976; 69:85-91
  • Muller D, Sievers E, Eggert P. Influence of hyperfiltration on the measurment of uri- nary NAG Pediatr. Nephrol. 1999; 13:519- 23
  • Lockwood TD, Bosmann HB: the use of urinary N-acetyl-beta-D-glucosaminidase in human renal toxicology 1. partial Biochemi- cal characterisation and excretion in hu- mans and release from the isolated perfused rat kidney. Toxicol and App Pharm. 1979; 49:323-336 edition, St Louisse Missouri.C.V. Mossby Company; 1982 p:3-18
  • Cooper EH, Forbes MA. Evaluation of a new test for N-acetyl-beta-D-glucosamini- dase in urine. Clin Chem. 1984; 30(4):593- 4.
  • Shimojo N, Kitahashi S, Naka K, et al. Com- parison of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase activities for evaluation of microangiopathy in diabetes mellitus. Metabolism 1987; 36(3):277-80.

İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması

Yıl 2011, Cilt: 64 Sayı: 1, 1 - 5, 01.01.2011

Klara Dalva Mevhibe Bal Gül Sevim Saydam Selime Ayaz İzak Dalva

https://doi.org/10.1501/Tipfak_0000000777

Öz

Amaç: Lizozomal bir enzim olan N-asetil-beta-D-glukozaminidaz (NAG), renal tübüler hasarın erken belirleyicilerinden biridir. Bu çalışmada NAG aktivitesinin ölçümünde kullanılabilecek güvenli ve kolayca uygulanabilir bir yöntemin belirlenmesi için p nitrophenyl N acetyl-B-D-glucosaminide (PNP-NAG) ve m, cresolsulfon phtaleinyl N, B, D glucosaminide (MCP-NAG) gibi kolorimetrik değerlendirme imkanı veren iki farklı substrat kullanılarak yöntemlerin karşılaştırılması amaçlanmıştır. Yöntem: Bu çalışmada 40 sağlıklı ve 40 böbrek yetmezliği olan hasta idrarındaki NAG aktiviteleri PNP-NAG ve MCP-NAG substratları ile ölçülerek, sonuçlar karşılaştırıldı. PNP NAG substratı ile çalışırken örnekler jel filtrasyonundan önce ve sonra reaksiyona sokularak jel filtrasyonunun sonuçları ne şekilde etkilediği test edildi. Bulgular: PNP-NAG (jel +), PNP-NAG (jel -) ve MCP-NAG yöntemleri ile elde edilen sonuçlar ortalama olarak sırasıyla, hasta grubunda sırasıyla (27.5 U/L, 25.96 U/L ve 16.5 U/L) kontrol grubuna sırasıyla (5.66 U/L, 5.38U/L ve 3.62 U/L) olup; değerler hasta grubunda kontrol grubuna göre yüksek bulunmuştur (p

Anahtar Kelimeler

İdrar N-asetil-D-glukosaminidaz Tübüler Hasar PNG-NAG MCP NAG

Kaynakça

  • Wellwood JM, Ellis BG, Price RG, et al . Urinary N-acetyl- beta-D-glucosaminidase activities in patients with renal disease. Br Med J. 1975; 3(5980):408-11.
  • Conchic J , Vindlay J, Levvy AG. Mamma- lian glycosidases: Distribution in the body. Biochem J 1959 ;77:318-325
  • Bourbouze R, Baumann FC, Bonvalet JP, et al. Distribution of N-acetyl-beta-D-glucosa- minidase isoenzymes along the rabbit neph- ron. Kidney Int. 1984; 4:636-42
  • Etherington C, Bosomworth M, Clifton I, et al. Measurement of urinary N-acetyl-b-D- glucosaminidase in adult patients with cystic fibrosis: before, during and after treatment with intravenous antibiotics. J Cyst Fibros. 2007; 1:67-73.
  • Moriguchi J, Inoue Y, Kamiyama S, et al. N-acetyl-beta-D-glucosaminidase (NAG) as the most sensitive marker of tubular dys- function for monitoring residents in non- polluted areas. Toxicol Lett. 2009;190(1):1- 8.
  • Jung K, Schulze BD, Sydow K. Diagnostic significance of different urinary enzymes in patients suffering from chronic renal diseas- es. Clin Chim Acta. 1987 ;1683:287-95.
  • Sherman RL, Drayer DE, Leyland-Jones BR, Reidenberg MM. N-acetyl-beta-glu- cosaminidase and beta 2-microglobulin. Their urinary excretion in patients with re- nal parenchymal disease. Arch Intern Med. 1983;143(6):1183-5.
  • Kang HK, Kim DK, Lee BH, et al Uri- nary N-acetyl-beta-D-glucosaminidase and malondialdehyde as a markers of renal dam- age in burned patients. J Korean Med Sci. 2001;16(5):598-602.
  • Kind PR. N-Acetyl-beta-D-glucosamini- dase in urine of patients with renal disease, and after renal transplants and surgery. Clin Chim Acta. 1982 ;119(1-2):89-97.
  • Sandman R, Margules RM, Kountz SL. Urinary lysosomal glycosidases after renal al- lotransplantation: Correlation of enzyme ex- cretion with allograft rejection and ischemia. Clin Chim Acta.1973;45(4):349-59.
  • Goren MP, Wright RK, Osborne S. Two automated procedures for N-acetyl-beta-D- glucosaminidase determination evaluated for detection of drug-induced tubular neph- rotoxicity. Clin Chem. 1986;32(11):2052-5.
  • Meyer BR, Fischbein A, Rosenman K, et al. Increased urinary enzyme excretion in work- ers exposed to nephrotoxic chemicals. Am J Med. 1984;76(6):989-98.
  • Etherington C, Bosomworth M, Clifton I , et al. Measurment of urinary N-Acetyl-beta- D-glucosaminidase in adult patients with cyctic fibrosis: Before, during and after treat- ment with intravenous antibiotics. Journal of Cyctic Fibrosis 2007; 6: 67-73
  • Mariguchi J, Inoue Y, Kamiyama S, et al. N-Acetyl-beta-D-glucosaminidase(NAG) as the most sensitive marker of tubuler dys- function for monitoring residents in non- polluted areas. Toxicology letters 2009; 190:1-8
  • Johnston ID, Jones NF, Scoble JE, et al. The diagnostic value of urinary enzyme measure- ments in hypertension. Clin Chim Acta. 1983;133(3):317-25.
  • Severini G, Aliberti LM, Di Girolamo M. N-acetyl-beta-glucosaminidase isoenzymes in serum and urine of patients with diabetes mellitus Clin Chem. 1988;34(12):2430- 2432
  • National Institute for Clinical Excellence. Management of type 2 diabetes. Renal dis- ease-prevention and early menagement clini- cal guideline. F. London : Natioanal Institute for Clinical Excellence 2002.
  • Basturk T, Altuntaş Y, Kurklu A, ve ark. Urinary N-Acetyl-beta-D-glucosaminidase as an earlier marker of diabetic nephropa- thy and influence of low-dose perindopril/ indapamide combination. Ren Fail 2006; 28(2):125-8
  • Ellis BG, Tucker SM, Thompson AE, et al. Presence of serum and tissue forms of N- acetyl-beta-glucosaminidase in urine from patients with renal disease. Clin Chim Acta. 1975; 64(2):195-202.
  • Kunin C M, Chesny R W, Craig W A, et al. Enzymuria as a glucosaminidase in the gen- eral population and in patients with renal disease . Pediatrics 1987; 62:751-760
  • Vigano A, Cavanna G, Capodaglio P, et al. Methodological and clinical aspects of uri- nary N-acetyl-glucosaminidase in pediatric subjects. Biochem Med. 1981;25(1):26-33.
  • Horak E, Hopfer SM, Sunderman FW Jr. Spectrophotometric assay for urinary N- acetyl-beta-D-glucosaminidase activity.Clin 29. Bauer JD Clinical Laboratory Methods 9th Chem.198; 27(7):1180-5.
  • Noto A, Ogawa Y, Mori S, et al. Simple, rap- id spectrophotometry of urinary N-acetyl- beta-D-glucosaminidase, with use of a new chromogenic substrate. Clin Chem. 1983; 29(10):1713-6.
  • Yuen CT, Price RG, Chattagoon L, et al. Colorimetric assays for N-acetyl-beta-D- glucosaminidase and beta-D-galactosidase in human urine using newly-developed omega-nitrostyryl substrates. Clin Chim Acta. 1982; 124(2):195-204.
  • Tassi C, Mancuso F, Feligioni L, et al. Ex- pression models of urinary N-Acetyl--D- glucosaminidase in patients with chronic renal insufficiancy. Clin Chim Acta 2004; 346:129-133
  • Welwood JM, Price RG, Ellis BG, et al. A note on the practical aspects of the assay of N-acetyl-beta-D-glucosaminidase. Clin Chim Acta 1976; 69:85-91
  • Muller D, Sievers E, Eggert P. Influence of hyperfiltration on the measurment of uri- nary NAG Pediatr. Nephrol. 1999; 13:519- 23
  • Lockwood TD, Bosmann HB: the use of urinary N-acetyl-beta-D-glucosaminidase in human renal toxicology 1. partial Biochemi- cal characterisation and excretion in hu- mans and release from the isolated perfused rat kidney. Toxicol and App Pharm. 1979; 49:323-336 edition, St Louisse Missouri.C.V. Mossby Company; 1982 p:3-18
  • Cooper EH, Forbes MA. Evaluation of a new test for N-acetyl-beta-D-glucosamini- dase in urine. Clin Chem. 1984; 30(4):593- 4.
  • Shimojo N, Kitahashi S, Naka K, et al. Com- parison of N-acetyl-beta-D-glucosaminidase and alanine aminopeptidase activities for evaluation of microangiopathy in diabetes mellitus. Metabolism 1987; 36(3):277-80.
Toplam 30 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Makaleler
Yazarlar

Klara Dalva Bu kişi benim

Mevhibe Bal Bu kişi benim

Gül Sevim Saydam Bu kişi benim

Selime Ayaz Bu kişi benim

İzak Dalva Bu kişi benim

Yayımlanma Tarihi 1 Ocak 2011
Yayımlandığı Sayı Yıl 2011 Cilt: 64 Sayı: 1

Kaynak Göster

APA Dalva, K., Bal, M., Saydam, G. S., Ayaz, S., vd. (2011). İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması. Ankara Üniversitesi Tıp Fakültesi Mecmuası, 64(1), 1-5. https://doi.org/10.1501/Tipfak_0000000777
AMA Dalva K, Bal M, Saydam GS, Ayaz S, Dalva İ. İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması. Ankara Üniversitesi Tıp Fakültesi Mecmuası. Ocak 2011;64(1):1-5. doi:10.1501/Tipfak_0000000777
Chicago Dalva, Klara, Mevhibe Bal, Gül Sevim Saydam, Selime Ayaz, ve İzak Dalva. “İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 64, sy. 1 (Ocak 2011): 1-5. https://doi.org/10.1501/Tipfak_0000000777.
EndNote Dalva K, Bal M, Saydam GS, Ayaz S, Dalva İ (01 Ocak 2011) İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması. Ankara Üniversitesi Tıp Fakültesi Mecmuası 64 1 1–5.
IEEE K. Dalva, M. Bal, G. S. Saydam, S. Ayaz, ve İ. Dalva, “İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması”, Ankara Üniversitesi Tıp Fakültesi Mecmuası, c. 64, sy. 1, ss. 1–5, 2011, doi: 10.1501/Tipfak_0000000777.
ISNAD Dalva, Klara vd. “İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması”. Ankara Üniversitesi Tıp Fakültesi Mecmuası 64/1 (Ocak 2011), 1-5. https://doi.org/10.1501/Tipfak_0000000777.
JAMA Dalva K, Bal M, Saydam GS, Ayaz S, Dalva İ. İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2011;64:1–5.
MLA Dalva, Klara vd. “İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması”. Ankara Üniversitesi Tıp Fakültesi Mecmuası, c. 64, sy. 1, 2011, ss. 1-5, doi:10.1501/Tipfak_0000000777.
Vancouver Dalva K, Bal M, Saydam GS, Ayaz S, Dalva İ. İdrar N-Asetil-Beta-D-Glukosaminidaz Aktivitesi: İki Farklı Tayin Yönteminin Karşılaştırılması. Ankara Üniversitesi Tıp Fakültesi Mecmuası. 2011;64(1):1-5.